MARKET

RLMD

RLMD

Relmada Therapeutics Inc
NASDAQ
4.830
+0.300
+6.62%
After Hours: 4.910 +0.08 +1.66% 19:31 12/31 EST
OPEN
4.530
PREV CLOSE
4.530
HIGH
4.840
LOW
4.440
VOLUME
809.98K
TURNOVER
--
52 WEEK HIGH
5.12
52 WEEK LOW
0.2404
MARKET CAP
354.20M
P/E (TTM)
-2.6878
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RLMD last week (1222-1226)?
Weekly Report · 12/29/2025 10:11
Ibio, RLMD, SEE, OLLI, Invivyd Trending With Analysts
TipRanks · 12/27/2025 09:00
enGene Holdings: A Potential Oncology Entrant
Seeking Alpha · 12/26/2025 21:00
Arcellx initiated, Cummins upgraded: Wall Street’s top analyst calls
TipRanks · 12/22/2025 14:50
This Blacksky Technology Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Benzinga · 12/22/2025 13:20
Relmada Therapeutics Price Target Announced at $9.00/Share by Jefferies
Dow Jones · 12/22/2025 12:29
Jefferies Initiates Coverage On Relmada Therapeutics with Buy Rating, Announces Price Target of $9
Benzinga · 12/22/2025 12:19
Weekly Report: what happened at RLMD last week (1215-1219)?
Weekly Report · 12/22/2025 10:11
More
About RLMD
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.

Webull offers Relmada Therapeutics Inc stock information, including NASDAQ: RLMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RLMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RLMD stock methods without spending real money on the virtual paper trading platform.